tbuckley/cabot-search huggingface dataset:
Prognostic ability of the Gustave Roussy Immune Score for patients with advanced pancreatic adenocarcinoma.
Authors: Lucy Xiaolu Ma, Nicholas Timothy Holzapfel, Yifan Wang, Stephanie Ramotar, Michael J Allen, Gun Ho Jang, Amy Zhang, Anna Dodd, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Joseph Biagi, Julie Wilson, Faiyaz Notta, Sandra Fischer, George Zogopoulos, Steven Gallinger, Robert C Grant, Jennifer J. Knox, Grainne M. O'Kane
Journal: Journal of Clinical Oncology (2022)

469 Background: The Gustave Roussy Immune Score (GRIm-S) considers a composite of neutrophil to lymphocyte ratio (&gt; 6 = 1), albumin (&lt; 35 = 1) and LDH (&gt; ULN = 1) and has been established as a prognostic score and may in aid in the selection of patients for phase 1 trials of immune checkpoint inhibitors. Methods: We explored the prognostic impact of the GRIm-S (high &gt; 1) in patients enrolled on the COMPASS trial and correlated the score with genomic and clinical characteristics. Patients in this trial had biopsies for whole genomic and RNA sequencing prior to standard chemotherapy regimens in the advanced setting. Results: 252 patients were included in the analyses with a median follow-up time of 28 months. 16% of patients had a high GRIm-S with significantly shorter median overall survival (OS) of 4.1 months versus 10.0 months in those with a low score (HR 2.18, 95% CI 1.4-3.4, p &lt; 0.0001). In the GRIm-S-high cohort, early progression with non-evaluable disease and disease progression were more common than in the GRIm-S low cohort (56% vs 31%, p = 0.003). In a multivariable analysis, a high GRIm-S was poorly prognostic (HR 1.6 95% CI 1.3-1.9, p &lt; 0.001), whereas the classical RNA subtype (vs. basal-like) (HR 0.41, 95% CI 0.3-0.6, p &lt; 0.001) and a high HRDetect score (HR 0.47 95% CI 0.3-0.7, p &lt; 0.001) associated with superior OS. The GRIm-S did not correlate with RNA subtypes or with specific KRAS mutations. There were no differences in structural variant load or tumour mutational burden between groups. However those with a high GRIm-S did have a higher total target lesion diameter at baseline (p &lt; 0.001). Conclusions: The GRIm-S identifies a subset of patients who have aggressive pancreas cancer and short life expectancy. This information may help clinicians in treatment decision making and selection for clinical trials.
AMA Council on Drugs. New names. List no. 109
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vitamin D and COVID-19: why the controversy?
Authors: None The Lancet Diabetes & Endocrinology
Journal: The Lancet Diabetes & Endocrinology (2021)

"To help retain the peak of sunny summer health—to help maintain rugged resistance to winter colds and sickness—drink Schlitz [beer], with Sunshine Vitamin D", reads an advertisement in the American Magazine from December, 1936.
Smoking cessation
Authors: I. Campbell
Journal: Thorax (2000)

Use of nicotine replacement therapies and the antidepressant bupropion helps people stop smoking.Smokers with clinical depression were excluded from a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects) and placebo (160 subjects) for smoking cessation.Treatment consisted of nine weeks of bupropion (150 mg per day for the first three days and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine patch therapy (21 mg per day during weeks 2-7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo.The target day for quitting smoking was usually day 8. Point-prevalence abstinence rate at 12 months were 15.6% for placebo, 16.4% for nicotine patch, 30.3% for bupropion (p<0.001) and 35.5% for bupropion plus nicotine patch (p< 0.001).311 subjects (34.8%) discontinued one or both medications, 79 because of adverse effects -6 (3.8%) on placebo, 16 (6.6%)on nicotine patches, 29 (11.9%) on bupropion and 28 (11.4%) on combined treatment.The most common adverse effects were insomnia and headache.Average weight gain at 7 weeks was significantly less in the combined treatment group (1.1 kg) than in the bupropion group (1.7 kg) and the placebo group (2.1 kg).The nicotine patch group gained 1.6 kg.Treatment with sustained-release bupropion or the combination of bupropion and the nicotine patch was more effective than nicotine patch alone or placebo but there was no significant difference between bupropion alone or bupropion in combination with a nicotine patch.(
Abstract 17402: Increased Epicardial Adipose Tissue Volume is Associated With Left Ventricular Diastolic Function in Patients With Zero Coronary Artery Calcium Score
Authors: Hiroto Utsunomiya, Hideya Yamamoto, Atsushi Shimada, Toshiro Kitagawa, Takayuki Hidaka, Yasuki Kihara
Journal: Circulation (2018)

Background: Recent publications suggested that epicardial adipose tissue (EAT) contributes to the pathogenesis of coronary atherosclerosis. Although some studies showed the association between EAT accumulation and left ventricular (LV) diastolic dysfunction, these associations are not fully understood. Methods: We evaluated 153 patients without coronary artery disease who underwent coronary computed tomography (CT) angiography and Doppler echocardiography. We evaluated 153 patients (mean age of 60 years and 54% men) with zero coronary artery calcium score in coronary CT. Visceral adipose tissue (VAT) area was simultaneously measured by abdominal scans, and EAT volume was also calculated. These measurements were corrected by body surface area; VAT area index (VATAI), and EAT volume index (EATVI). The early diastolic mitral annular velocity at the septal (septal E’) and lateral (lateral E’) were measured using tissue Doppler echocardiography. Results: The mean values of BMI, VATAI, EATVI, and LVMI were 23.7 ± 3.8 kg/m 2 , 52.6 ± 26.4 cm 2 /m 2 , 71.3 ± 29.8 cm 3 /m 2 , and 83.3 ± 17.7 g/m 2 , respectively. The mean septal E’ and lateral E’ velocities were 7.2 ± 2.2 cm/s and 9.8 ± 2.9 cm/s, respectively. Each E’ velocity was negatively correlated with EATVI (septal, R = 0.276, p &lt; 0.001; lateral, R = 0.342, p &lt; 0.001) and VATAI (septal, R = 0.241, p = 0.03; lateral, R = 0.255, p = 0.002; Figure). In contrast, each E’ velocity was not correlated with LVMI (septal, R = 0.161, p = 0.03; lateral, R = 0.118, p = 0.14) and BMI (septal, R = 0.182, p = 0.03; lateral, R = 0.152, p = 0.06). To determine each E’ velocity, we performed stepwise multiple regression analyses where all clinical parameters were entered. Diastolic blood pressure (p = 0.014), statin use (p = 0.011), LVMI (p = 0.003), and EATVI (p = 0.004) were independently correlated with septal E’ velocity, and statin use (p = 0.024), LVMI (p = 0.011), and EATVI (p &lt; 0.001) were independently correlated with lateral E’ velocity. Conclusion: An increase in EATVI was associated with the decrease of early diastolic mitral annular velocity along each side of the left ventricle in patients with coronary calcium score of zero. These findings indicate that EAT accumulation may cause LV diastolic dysfunction in the early phase of coronary artery disease.
Bed utilization improved by planned hospital procedures
Authors: P. L. Rossman
Journal: JAMA (1971)

Due to the acute shortage of hospital beds and the need for physicians to curb rising health expenses, it is desirable to save the patient hospital days whenever possible. Time can be lost in the admission and discharge of patients as well as in the diagnostic work-up in the clinical laboratory, radiology department, nuclear medicine section, and other departments. Attention to test combinations and the time sequence of procedures will shorten the hospital stay for many patients. The following recommendations will provide more efficient utilization of hospital facilities. <h3>General</h3> A hospital preadmission order form can be completed in the doctor's office or at the patient's home and sent in an envelope with the patient to the hospital. The hospital nurse then loses no time looking for the doctor to get admission orders. Patient care can thus be started promptly. The envelope is retained by the patient; printed on it is
Deaths
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract PS11-41: A spatially resolved single cell atlas of the human breast
Authors: Kai Kessenbrock
Journal: Cancer Research (2021)

Abstract The human breast consists of lobules connected to an intricate network of ducts that are surrounded by fatty tissues, designed to produce and transport milk to nourish offspring. Histopathology has identified 10 major cell types based on morphological features but have provided limited information on cell states - the transcriptional programs of cell types that reflect different biological functions. In this study we have generated an unbiased ‘cell atlas’ of the normal human breast to define the cell types and cell states using single cell RNA sequencing and spatial transcriptomics methods. We performed 3’ microdroplet based single cell and nuclei RNA sequencing of 248,687 stromal cells and 89,301 nuclei from 35 women with pathologically normal breast tissues that were collected from mastectomies and reduction mammoplasties. Unbiased expression analysis identified four major cell types: adipocytes, epithelial cells (luminal and basal), fibroblasts and endothelial cells and defined their transcriptional programs. Additionally, 8 minor cell types were identified in the breast, including macrophages, T-cells, natural killer cells, mast cells, pericytes, apocrine cells, neurons and smooth muscle cells. Our data revealed hundreds of novel markers of these cell types and defined their transcriptional programs and cell states. Most cell types had multiple transcriptional programs including luminal epithelial cells (hormone receptor positive and secretory), basal epithelial cells (myoepithelial or basal), endothelial cells (E1, E2, E3), myeloid cells, T-cells and fibroblasts (F1-F4) and provided insight into developmental lineages. We further delineated the spatial organization of these cell types and cell states within the tissue architecture via a 34 antibody CODEX ultra-high plex immunofluorescence imaging experiment. Antibodies were targeted against epithelial, endothelial and immune cells and imaging data were acquired at single cell resolution from breast tissues measuring up to 35mm2. Cell phenotypes were independently clustered, correlated to transcriptomic data and cellular neighborhoods were mapped using nearest neighbor approximations. The breast cell atlas data provides an invaluable normal reference for the research community to understand how normal cell types are reprogrammed in diseases such as breast cancer. Citation Format: Kai Kessenbrock. A spatially resolved single cell atlas of the human breast [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS11-41.
NOGA electro-mechanical characteristics of non-ischemic dilated c ardiomyopathy S. Chiu Wong, Barry Cohen, Stylianos Papakodos, Mark Blum, Mohsen Mabudian, Mark Reisman. The New York Presbyterian Hospital-Cornell Campus, New York, NY, Morristown Memorial Hospital, Morristown, NJ
Journal: Journal of the American College of Cardiology (2001)
Final clinical outcome and biomarker analysis of sintilimab plus a bevacizumab biosimilar (IBI305) for advanced hepatocellular carcinoma: A phase Ib clinical trial.
Authors: Wen Zhang, Caifeng Gong, Xinyu Bi, Peng Xuenan, Yongkun SUN, Yan Wang, Hui Zhou, Hong Zhao, Jianqiang Cai, Ai-Ping Zhou
Journal: Journal of Clinical Oncology (2022)

455 Background: The combination of immune checkpoint inhibitors (ICI) and vascular endothelial growth factor (VEGF) antibodies manifested high efficacy in advanced hepatocellular carcinoma (HCC), which still needs to be further verified. We aimed to evaluate the safety and activity of this strategy with different doses, as well as to explore potential predictive biomarkers. Methods: In this two-part phase Ib study, patients with advanced or metastatic HCC were enrolled. Part 1 was dose escalation trial with sintilimab plus bevacizumab biosimilar (IBI305) 7.5 mg/kg (initial dose) or 15 mg/kg (escalated dose). Part 2 was extension in each tolerable dose group. Peripheral blood samples and tumor tissue specimens were collected before treatment to detect serum cytokines and tumor immune microenvironment (TiME) by multiplexed bead immunoassays and multicolor immunofluorescence. Results: Fifty patients were enrolled in final analysis. Among all, IBI305 7.5 mg/kg was administered in 29 patients and 21 patients with 15 mg/kg. The most common adverse event suspected to be treatment-related was hypertension (32%), proteinuria (26%) and fever (26%). The incidence of the grade 3-5 adverse events in group 15 mg/kg was 28.6%, while 13.8% in 7.5 mg/kg group. Overall, the ORR was 34% (17/50) and the DCR reached to 78% (39/50). The median PFS was 10.5 months (95%CI, 8.4-12.7) and the median OS was 20.2 months (95%CI, 16.1 -24.3). The ORR for 7.5 mg/kg and 15 mg/kg were 31% and 38%, respectively. Further analysis showed that responder patients (CR+PR+SD≥12 weeks) had significantly higher level of serum CD137 than those with non-responder group (PD+SD≥12weeks) (median, 32.8 versus 19.8 pg/mL, P = 0.034). Patients with a high level of CD137 ≥ 31.8 pg/mL had longer PFS (mPFS:14.2 vs. 4.1months, P = 0.001) and OS (mOS: NR vs.15.6months, P = 0.023). In addition, the TiME analysis demonstrated that the density of M1 macrophages (CD68+CD163-) in stroma was related to efficacy (P = 0.033), longer PFS (P = 0. 024) and OS (P = 0.046). Conclusions: The sintilimab plus IBI305 is well tolerated and effective, IBI305 of 7.5 mg/kg could be also optional to some patients. The serum CD137 and M1 macrophages are potential predicting biomarkers for the combination therapy Clinical trial information: NCT04072679.
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274–82
Authors: Giulio Francolini, Lucia P. Ciccone, Lorenzo Livi
Journal: European Urology (2022)
The morality of transplantation
Journal: JAMA (1991)

<h3>To the Editor.</h3> —Cohen and Benjamin<sup>1</sup>argue that since the medical profession does not generally offer less care to patients with moral failings or undesirable behavior, we should not assign alcoholics a lower priority for liver transplantation. This argument is faulty. The medical profession often allocates resources based on a patient's behavior and sometimes based on a patient's moral worth. It is highly unlikely that a current smoker who has severe, irreversible heart and lung disease would be eligible for a heart-lung transplant. When allocating scarce medical resources, a person's potential value to society is often considered. If two patients are undergoing chronic renal dialysis and one donor kidney becomes available, a teenager would get priority over a septuagenarian, and an engineer would get priority over a convicted felon. Cohen and Benjamin also argue that even if alcoholism is a moral failing, we are not justified in discriminating against
Dr. McKusick, Not McCusick
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
scDALI: modeling allelic heterogeneity in single cells reveals context-specific genetic regulation
Authors: Tobias Heinen, Stefano Secchia, James P. Reddington, Bingqing Zhao, Eileen E. M. Furlong, Oliver Stegle
Journal: Genome biology (2022)

Abstract While it is established that the functional impact of genetic variation can vary across cell types and states, capturing this diversity remains challenging. Current studies using bulk sequencing either ignore this heterogeneity or use sorted cell populations, reducing discovery and explanatory power. Here, we develop scDALI, a versatile computational framework that integrates information on cellular states with allelic quantifications of single-cell sequencing data to characterize cell-state-specific genetic effects. We apply scDALI to scATAC-seq profiles from developing F1 Drosophila embryos and scRNA-seq from differentiating human iPSCs, uncovering heterogeneous genetic effects in specific lineages, developmental stages, or cell types.
The surface coating of iron oxide nanoparticles drives their intracellular trafficking and degradation in endolysosomes differently depending on the cell type
Authors: Yadileiny Portilla, Vladimir Mulens-Arias, Alberto Paradela, Antonio Ramos-Fernández, Sonia Pérez-Yagüe, M. Puerto Morales, Domingo F. Barber
Journal: Biomaterials (2022)

Magnetic nanoparticles (MNPs) are potential theranostic tools that are biodegraded through different endocytic pathways. However, little is known about the endolysosomal network through which MNPs transit and the influence of the surface coating in this process. Here, we studied the intracellular transit of two MNPs with identical iron oxide core size but with two distinct coatings: 3-aminopropyl-trietoxysilane (APS) and dimercaptosuccinic acid (DMSA). Using endolysosomal markers and a high throughput analysis of the associated proteome, we tracked the MNPs intracellularly in two different mouse cell lines, RAW264.7 (macrophages) and Pan02 (tumor cells). We did not detect differences in the MNP trafficking kinetics nor in the MNP-containing endolysosome phenotype in Pan02 cells. Nonetheless, DMSA-MNPs transited at slower rate than APS-MNPs in macrophages as measured by MNP accumulation in Rab7+ endolysosomes. Macrophage DMSA-MNP-containing endolysosomes had a higher percentage of lytic enzymes and catalytic proteins than their APS-MNP counterparts, concomitantly with a V-type ATPase enrichment, suggesting an acidic nature. Consequently, more autophagic vesicles are induced by DMSA-MNPs in macrophages, enhancing the expression of iron metabolism-related genes and proteins. Therefore, unlike Pan02 cells, the MNP coating appears to influence the intracellular trafficking rate and the endolysosome nature in macrophages. These results highlight how the MNP coating can determine the nanoparticle intracellular fate and biodegradation in a cell-type bias.
Percutaneous myocardial revascularization with a newly developed high pressure saline-jet system: Evaluation of acute and chronic effects in porcine hearts Christian M. Spaulding, Luis C�sar Guarita Souza, Pascal Richard, Bruno Pouzet, Russ Bowden, Bettina Faas, Frederique Tissier, Marie-C�cile Vacher-Lavenu. Cochin Hospital, Rene Descartes University, Paris, France, Ecole de Chirurgie de l'AP-HP, Paris, France
Journal: Journal of the American College of Cardiology (2001)